MAP2K7 and melanoma: We observed an increase in ROS levels after a short-term 3 day treatment of BRAF and MEK inhibitors, indicating that ROS levels were upregulated in an in vivo mouse melanoma model subjected to acute treatment of dabrafenib and trametinib (Figure 1C).